China’s Prestigious Oncology Event: 2024 CSCO Annual Meeting Held in Xiamen

China’s Prestigious Oncology Event: 2024 CSCO Annual Meeting Held in Xiamen

2024.09.28
Xiamen, China, September 25-29, 2024 — The 27th National Clinical Oncology Conference and the 2024 Academic Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) commenced in Xiamen, embracing the theme "Patient-Centric, Shared Future." Jointly organized by the CSCO and the CSCO Foundation, the conference has brought together top experts and elites in oncology from both domestic and international fields to discuss the latest advancements, cutting-edge technologies, and future trends in cancer prevention and treatment.
Chinese Innovative Drug Takes the International Stage, Offering New Treatment Options for Intermediate and High-Risk Myelofibrosis Patients

Chinese Innovative Drug Takes the International Stage, Offering New Treatment Options for Intermediate and High-Risk Myelofibrosis Patients

2024.09.26
From September 13 to 17, 2024, the European Society for Medical Oncology (ESMO) Annual Meeting is being held in Barcelona, Spain. As one of the top international oncology conferences, the event gathers experts and scholars from around the world to share cutting-edge research and discuss future developments. In the Mini Oral Session on Hematologic Malignancies, Dr. Ling Pan from West China Hospital, Sichuan University, presented a pivotal phase II study comparing rovatirelinib with hydroxyurea for the treatment of intermediate and high-risk myelofibrosis (MF). The results demonstrated significant benefits in both efficacy and safety for rovatirelinib, offering a new potential treatment option for MF patients. Hematology Frontier invited Dr. Ling Pan to discuss the current landscape and challenges in the diagnosis and treatment of MF, provide insights into this pivotal study, and share her experiences at the ESMO conference.
Dr. Feng Shen: Climb to the peak! The ASAP model continues to break through the depth and breadth of screening for Chinese liver cancer risk groups

Dr. Feng Shen: Climb to the peak! The ASAP model continues to break through the depth and breadth of screening for Chinese liver cancer risk groups

2024.09.25
China is a major country with liver cancer, and the incidence rate and mortality rate of liver cancer account for about half of the world's total. Early identification of high-risk populations and early diagnosis of liver cancer are key to improving the overall survival rate of patients. Since the discovery of vitamin K in 1929, researchers have gradually confirmed the important role of serum abnormal prothrombin caused by its deficiency in the diagnosis of liver cancer. In 2019, Dr. Feng Shen and his team from Eastern Hepatobiliary Surgery Hospital, the third affiliated hospital of the Naval Medical University, collaborated with other top hospital teams in China to establish and validate the ASAP risk prediction model. Since then, the ASAP model has continuously broken through the prediction limitations of hepatitis B-related liver cancer, and has achieved frequent success in predicting hepatitis C-related liver cancer, non-alcoholic fatty liver disease-related liver cancer, and early recurrence diagnosis of liver cancer.
Efficacy and Safety of Dual-target CAR-T Therapy for Newly Diagnosed High-Risk Multiple Myeloma

Efficacy and Safety of Dual-target CAR-T Therapy for Newly Diagnosed High-Risk Multiple Myeloma

2024.09.15
The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held in Madrid, Spain, from June 13 to 16, 2024. At this EHA conference, a study (S200) by Professors Juan Du and Jing Lu from Shanghai Changzheng Hospital was selected for an oral presentation. This study explored the efficacy and safety of GC012F in the first-line treatment of newly diagnosed high-risk multiple myeloma patients eligible for transplantation. To discuss the study and the treatment of multiple myeloma, "Oncology Frontier - Hematology Frontier" conducted an interview with Professor Jing Lu.
Professor Qian Jiang: Exploring New Models of Regional Academic Exchange, Beijing Hematology Academic Annual Meeting Concludes Successfully

Professor Qian Jiang: Exploring New Models of Regional Academic Exchange, Beijing Hematology Academic Annual Meeting Concludes Successfully

2024.09.13
On July 5th, the 17th Beijing Hematology Academic Annual Meeting, hosted by the Beijing Medical Association Hematology Branch, concluded successfully in Beijing. This year's meeting featured innovative and unique formats and rich content, providing a platform for participants to share cutting-edge advancements and experiences. It also showcased the original research achievements in the field of hematology in Beijing. "Oncology Frontier - Hematology Frontier" invited Professor Qian Jiang, the current chair of the Beijing Medical Association Hematology Branch, the main organizer of this conference, and a professor at Peking University People's Hospital, to share the highlights and unique aspects of the meeting and to discuss its far-reaching impacts on the future.
Dr. Shenmiao Yang: Navigating the New Era of CLL Treatment with Long-Term and Short-Term Approaches

Dr. Shenmiao Yang: Navigating the New Era of CLL Treatment with Long-Term and Short-Term Approaches

2024.09.11
With the widespread adoption of chemotherapy-free treatment regimens and breakthroughs in targeted therapies, chronic lymphocytic leukemia (CLL) treatment has entered a new era. At the 12th Lu Daopei Hematology Forum, Hematology Frontier invited Dr. Shenmiao Yang from Peking University People’s Hospital to provide an in-depth analysis of the current state of CLL treatment in China, discuss future research directions, and explore new chapters in the development of the field.
Early Detection of Minimal Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA

Early Detection of Minimal Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA

2024.09.10
Recently, Professor Xiaofan Zhu, Director of the Division of Pediatric Hematology and Oncology Center at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Associate Chief Physician Doctor Min Ruan and Attending Doctor LiPeng Liu collaborated on a study titled "Early Detection of Minimal Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA," published in Clinical Cancer Research (with an impact factor of 11.5). This prospective study was the first to evaluate the longitudinal changes of ctDNA from plasma in patients, as compared to NGS based bone marrow DNA, for the early detection of relapse in children with AML.
Dr. Jun Ma: Gathering Global Experts to Discuss Cutting-Edge Advances and Core Concepts | The 8th CSCO Annual Hematology Conference

Dr. Jun Ma: Gathering Global Experts to Discuss Cutting-Edge Advances and Core Concepts | The 8th CSCO Annual Hematology Conference

2024.09.05
In the sweltering summer, we gather in Ice City. The “8th Annual Hematology Conference” organized by the Chinese Society of Clinical Oncology (CSCO), the CSCO Leukemia Expert Committee, and the CSCO Lymphoma Expert Committee, and hosted by the Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was grandly held in Harbin from July 26 to 28, 2024. Renowned experts and scholars from both domestic and international arenas came together to present and discuss research in leukemia, lymphoma, and myeloma, as well as address hot topics in clinical practice. On the first day of the conference, we were honored to interview Dr. Jun Ma, the conference chairman and director of the Harbin Institute of Hematology and Oncology, to share the hi